Results 21 to 30 of about 1,266 (177)

Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD

International Journal of COPD, 2020
Stefan Andreas,1,2 Lorcan McGarvey,3 Ulrich Bothner,4 Matthias Trampisch,4 Alberto de la Hoz,4 Matjaz Fležar,5 Roland Buhl,6 Peter Alter7 1Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany ...
Andreas S, McGarvey L, Bothner U, Trampisch M, de la Hoz A, Fležar M, Buhl R, Alter P   +7 more
doaj   +3 more sources

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease

International Journal of COPD, 2017
Chunxue Bai,1 Masakazu Ichinose,2 Sang Haak Lee,3 Kwan Ho Lee,4 Olaf Jöns,5 Ulrich Bothner,6 Yihua Zhao,7 Roland Buhl8 1Department of Pulmonary Medicine, Shanghai Respiratory Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China;
Bai C, Ichinose M, Lee SH, Lee KH, Jöns O, Bothner U, Zhao Y, Buhl R   +7 more
doaj   +1 more source

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD

ClinicoEconomics and Outcomes Research, 2016
Abigail Tebboth,1 Andrew Ternouth,1 Nuria Gonzalez-Rojas2 1Boehringer Ingelheim Ltd., Bracknell, UK; 2Boehringer Ingelheim GmBH, Ingelheim, Germany Objective: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic ...
Tebboth A, Ternouth A, Gonzalez-Rojas N
doaj   +1 more source

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function

International Journal of COPD, 2016
Christina Kunz,1 Doreen Luedtke,1 Anna Unseld,2 Alan Hamilton,3 Atef Halabi,4 Martina Wein,5 Stephan Formella6 1Translational Medicine and Clinical Pharmacology, 2Global Biometrics and Clinical Applications, Boehringer Ingelheim Pharma GmbH and Co KG ...
Kunz C, Luedtke D, Unseld A, Hamilton A, Halabi A, Wein M, Formella S   +6 more
doaj   +1 more source

Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. [PDF]

Respiratory Medicine, 2015
BACKGROUND: Tiotropium + olodaterol improves lung function and symptoms compared to monotherapies in chronic obstructive pulmonary disease (COPD). The OTEMTO 1 and 2 studies investigated the effects of tiotropium + olodaterol on lung function and health ...
Bennett, Nathan, Ferguson, Gary T, Grönke, Lars, Hallmann, Christoph, Abrahams, Roger, Schmidt, Olaf, Ferguson, Gary T., Bjermer, Leif, Singh, Dave, Bolitschek, Josef   +9 more
core   +3 more sources

Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results

International Journal of COPD, 2019
Martine Hoogendoorn,1 Isaac Corro Ramos,1 Michael Baldwin,2 Laura Luciani,3 Cecile Fabron,4 Bruno Detournay,4 Maureen PMH Rutten-van Mölken1,5 1institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, the ...
Hoogendoorn M, Corro Ramos I, Baldwin M, Luciani L, Fabron C, Detournay B, Rutten-van Mölken MPMH   +6 more
doaj   +1 more source

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol

International Journal of COPD, 2014
Neil S Roskell,1 Antonio Anzueto,2 Alan Hamilton,3 Bernd Disse,4 Karin Becker5 1Statistics, Bresmed Health Solutions Ltd, Sheffield, UK; 2School of Medicine, University of Texas Health Science Center, San Antonio, TX, USA; 3Medical Department, Boehringer
Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K   +4 more
doaj   +1 more source

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD [PDF]

European Respiratory Journal, 2017
Two replicate, double-blind, 6-week, incomplete-crossover studies (MORACTO 1 and 2) assessed the effects of tiotropium/olodaterol on inspiratory capacity and exercise endurance time in patients with moderate to severe chronic obstructive pulmonary ...
Alan Hamilton, Wenqiong Xue, Kirsten, Anne, Peter Frith, De Sousa, Dorothy, Dorothy De Sousa, Frith, Peter, Denis E. O'Donnell, François Maltais, O'Donnell, Denis E, Casaburi, Richard, Xue, Wenqiong, Anne Kirsten, Hamilton, Alan, Richard Casaburi, Maltais, François   +15 more
core   +6 more sources

Olodaterol + tiotropium bromide for the treatment of COPD

Expert Review of Respiratory Medicine, 2016
Patients suffering from COPD not controlled by a single bronchodilator should be given two bronchodilators with different mechanisms of action. Addition of a LABA to a LAMA induces a larger bronchodilation than that obtained with the LAMA as monotherapy ...
Puxeddu E., Cazzola M, Calzetta, L, Ciaprini C, Calzetta L, Ciaprini, C, Cazzola, M, Puxeddu, E, Calzetta L., Ciaprini C., Puxeddu E, Cazzola M.   +11 more
core   +5 more sources

Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease

International Journal of COPD, 2015
Wijdan H Ramadan,1 Wissam K Kabbara,1 Ghada M El Khoury,1 Sarah A Al Assir21Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, Byblos, Lebanon; 2School of Pharmacy, Lebanese American University, Byblos, LebanonAbstract ...
Ramadan WH, Kabbara WK, El Khoury GM, Al Assir SA   +3 more
doaj   +1 more source